MRK catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 19, 2026Sponsor estimate | NCT05597306Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid LeukemiaTerrence J Bradley, MD · Acute Myeloid Leukemia | MRKCollaborator | Phase 1 | Recruiting | Locked | Locked | Locked |
| Nov 20, 2026Sponsor estimate | NCT04634877Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly...Merck Sharp & Dohme LLC · Endometrial Neoplasms | MRKLead | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
| Nov 30, 2026Sponsor estimate | NCT06960655Improving Lipid Optimization Quality and Treatment Options in ASCVDBrigham and Women's Hospital · Hypercholesterolemia | MRKCollaborator | No phase registered | Enrolling by invitation | Locked | Locked | Locked |
- Primary completion Nov 19, 2026Sponsor estimatePhase 1NCT05597306Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid LeukemiaTerrence J Bradley, MD · Acute Myeloid LeukemiaRecruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 20, 2026Sponsor estimatePhase 3NCT04634877Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly...Merck Sharp & Dohme LLC · Endometrial NeoplasmsActive, not recruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimateNo phase registeredNCT06960655Improving Lipid Optimization Quality and Treatment Options in ASCVDBrigham and Women's Hospital · HypercholesterolemiaEnrolling by invitationMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 1, 2026Sponsor estimatePhase 2NCT05491226Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and RadiationStephen Shiao · TNBC - Triple-Negative Breast CancerRecruitingMRKCollaboratorINCYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 5, 2026Sponsor estimatePhase 1/Phase 2NCT04421560Pembrolizumab, Ibrutinib and Rituximab in PCNSLDana-Farber Cancer Institute · Primary Central Nervous System LymphomaRecruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 11, 2026Sponsor estimatePhase 2NCT04879329A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2Seagen, a wholly owned subsidiary of Pfizer · Urothelial CarcinomaRecruitingPFELeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 14, 2026Sponsor estimatePhase 1NCT07776665A Clinical Trial of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-044)Merck Sharp & Dohme LLC · HealthyActive, not recruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimatePhase 2NCT03684278Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind, Placebo-controlled, Multi-centre Trial (RAPID-I)University of Liverpool · Acute PancreatitisRecruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimatePhase 1/Phase 2NCT04585750The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PMV Pharmaceuticals, Inc · Advanced Solid TumorRecruitingPMVPLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimatePhase 1/Phase 2NCT05669430A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor MalignanciesGV20 Therapeutics · Solid Tumor, AdultRecruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimatePhase 2NCT06066957Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant RecipientsUniversity of Pennsylvania · Cytomegalovirus InfectionsActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimatePhase 1NCT07748351A Clinical Trial of Multiple Formulations of MK-4082 in Healthy Overweight and Obese Participants (MK-4082-007)Merck Sharp & Dohme LLC · HealthyActive, not recruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 16, 2026Sponsor estimatePhase 2NCT05756569Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant HistologyEmory University · Bladder Squamous Cell CarcinomaRecruitingPFECollaboratorMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 13 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.